Company Overview of Affibody Medical AB (publ)
Affibody Medical AB (publ), a biotechnology company, focuses on developing biopharmaceuticals based on its Affibody molecules and Albumod proprietary technology platforms. The Affibody technology includes the Affibody molecules, which are antibody mimetics that surpasses monoclonal antibodies and antibody fragments. The Albumod technology enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. It has collaboration agreements with Algeta ASA, Amylin, Daiichi Sankyo, Daewoong, Swedish Orphan Biovitrum, and GE Healthcare Bio-Sciences AB. The company was formerly known as Affibody Holding AB (publ) and changed its name to Affibody...
Gunnar Asplunds Alle 24
Solna, 171 63
Founded in 1998
Key Executives for Affibody Medical AB (publ)
Co-Founder, Deputy Chairman and Member of Scientific Advisory Board
Co-Founder, Chief Business Officer and Member of Technical Advisory Board
Co-Founder and Senior Vice President of Operations
Co-Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Affibody Medical AB (publ) Key Developments
Nordic Nanovector ASA and Affibody AB Enter into Three-Year Collaborative Research Agreement to Discover and Develop New Advanced Radio-Immunotherapies for Multiple Myeloma
Nov 27 14
Nordic Nanovector ASA and Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Backed by a Eurostars grant the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary to start GMP manufacturing of the Affibody®-based RIT and subsequently start clinical trials. The companies have been awarded approximately €1 million in total by Vinnova in Sweden and The Norwegian Research Council in Norway. Upon a successful conclusion of the collaboration Nordic Nanovector will have the opportunity to license the global rights to the Affibody®- based RIT. The development of an Affibody®-based RIT treatment represents a distinct work stream to be carried out in parallel with Nordic Nanovector’s lead product candidate Betalutin™ for non-Hodgkin Lymphoma treatment.
Affibody Medical AB (publ) Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Affibody Medical AB (publ) Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries